RxDoctor Payments Data

Laurie Bossory, MD

Interventional Cardiology · Ypsilanti, MINPI 1528453859

Payments from drug & device makers

$1,707in general payments, 2019–2025

Across 31 payments — averaging $55.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$405
  • Boston Scientific$320
  • Abiomed$275
  • AstraZeneca$129
  • Johnson & Johnson$122
  • Inari Medical, Inc.$105
  • plus $351 from 10 others

What the payments were for

  • Food & beverage$1,707100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,707 in reported general payments places this provider in the 15th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$58,447
Medicare patients
604
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$77,817
XareltoRivaroxaban24$33,553
Repatha SureclickEvolocumab29$32,392
EntrestoSacubitril/Valsartan25$30,513
Metoprolol Succinate149$2,157
Atorvastatin Calcium173$2,053
Rosuvastatin Calcium81$1,244
Ezetimibe42$1,045
Prasugrel Hcl13$956
Losartan Potassium84$833
Amiodarone Hcl15$656
Carvedilol86$644
Diltiazem 24hr Er (Cd)Diltiazem Hcl14$582
Isosorbide Mononitrate ErIsosorbide Mononitrate33$550
ClopidogrelClopidogrel Bisulfate21$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$77,81779 claims
Johnson & JohnsonXarelto$122$33,55324 claims
NovartisEntresto$19$30,51325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Ypsilanti

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →